These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23782591)

  • 41. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
    Lockhart IA; Mitchell SA; Kelly S
    Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alzheimer's disease multiple intervention trial (ADMIT): study protocol for a randomized controlled clinical trial.
    Callahan CM; Boustani MA; Schmid AA; Austrom MG; Miller DK; Gao S; Morris CS; Vogel M; Hendrie HC
    Trials; 2012 Jun; 13():92. PubMed ID: 22737979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
    Scharre DW; Vekeman F; Lefebvre P; Mody-Patel N; Kahler KH; Duh MS
    Drugs Aging; 2010 Nov; 27(11):903-13. PubMed ID: 20964464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
    Dou KX; Tan MS; Tan CC; Cao XP; Hou XH; Guo QH; Tan L; Mok V; Yu JT
    Alzheimers Res Ther; 2018 Dec; 10(1):126. PubMed ID: 30591071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
    Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
    Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Donepezil: an update.
    Seltzer B
    Expert Opin Pharmacother; 2007 May; 8(7):1011-23. PubMed ID: 17472546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maintaining functional and behavioral abilities in Alzheimer disease.
    Winblad B
    Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S34-40. PubMed ID: 11669508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
    Haywood WM; Mukaetova-Ladinska EB
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Donepezil: a review.
    Seltzer B
    Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):527-36. PubMed ID: 16863459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study.
    Olde Rikkert MG; Verhey FR; Blesa R; von Arnim CA; Bongers A; Harrison J; Sijben J; Scarpini E; Vandewoude MF; Vellas B; Witkamp R; Kamphuis PJ; Scheltens P
    J Alzheimers Dis; 2015; 44(2):471-80. PubMed ID: 25322923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.
    Halminen O; Vesikansa A; Mehtälä J; Hörhammer I; Mikkola T; Virta LJ; Ylisaukko-Oja T; Linna M
    J Alzheimers Dis; 2021; 81(3):1103-1115. PubMed ID: 33843673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
    Ma SL; Tang NLS; Wat KHY; Tang JHY; Lau KH; Law CB; Chiu J; Tam CCW; Poon TK; Lin KL; Kng CPL; Kong HL; Chan TY; Chan WC; Lam LCW
    Am J Alzheimers Dis Other Demen; 2019 Aug; 34(5):302-307. PubMed ID: 31064198
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.